Price
$15
Increased by 0.00%
Dollar Volume
7.03 M
ADR%
0.17
Earnings Report Date (estimate)
Mar 13, 23 (-0.06)
Market Cap.
521.45 M
Shares Float
34.34 M
Shares Outstanding
34.76 M
Beta
0.98
Price / Earnings
-12.47
BPR
659.82
20D Range
14.91 15.00
50D Range
14.74 15.00
200D Range
3.41 15.00
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 7, 22 -0.09
Increased by +70.00%
-0.18
Increased by +50.00%
Aug 4, 22 -0.24
Increased by +40.00%
-0.28
Increased by +14.29%
May 5, 22 -0.30
Increased by +62.96%
-0.25
Decreased by -20.00%
Mar 14, 22 -0.21
Increased by +52.27%
-0.29
Increased by +27.59%
Nov 8, 21 -0.30
Increased by +9.09%
-0.36
Increased by +16.67%
Aug 5, 21 -0.40
Increased by +4.76%
-0.45
Increased by +11.11%
May 10, 21 -0.81
Decreased by -55.77%
-0.55
Decreased by -47.27%
Mar 16, 21 -0.44
Decreased by -57.14%
-0.38
Decreased by -15.79%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 30.45 M
Increased by +100.68%
-3.27 M
Increased by +68.50%
Decreased by -10.73%
Increased by +84.30%
Jun 30, 22 25.30 M
Increased by +234.89%
-8.32 M
Increased by +38.82%
Decreased by -32.88%
Increased by +81.73%
Mar 31, 22 20.92 M
Increased by +989.58%
-10.20 M
Increased by +53.90%
Decreased by -48.75%
Increased by +95.77%
Dec 31, 21 -8.50 M
Decreased by -1.06 K%
-7.25 M
Increased by +36.93%
Increased by +85.31%
Increased by +106.57%
Sep 30, 21 15.17 M
Increased by +321.47%
-10.37 M
Decreased by -23.53%
Decreased by -68.33%
Increased by +70.69%
Jun 30, 21 7.56 M
Increased by +908.81%
-13.60 M
Decreased by -86.11%
Decreased by -179.95%
Increased by +81.55%
Mar 31, 21 1.92 M
Increased by +144.90%
-22.12 M
Decreased by -163.95%
Decreased by -1.15 K%
Decreased by -7.78%
Dec 31, 20 886.00 K
Increased by +15.97%
-11.50 M
Decreased by -157.88%
Decreased by -1.30 K%
Decreased by -122.37%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

AVEO Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company, focuses on developing and commercializing medicines for patients with cancer. It markets FOTIVDA, an oral, next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC). The company is also developing tivozanib for the treatment of RCC, hepatocellular carcinoma, ovarian cancer, immunologically cold tumors, and cholangiocarcinoma. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma, pancreatic cancer, and acute myeloid leukemia; AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; AV-203, a potent humanized IgG1 monoclonal antibody that targets ErbB3; and AV-353 that targets the Notch 3 pathway. The company has collaborations and license agreements with AstraZeneca PLC; EUSA Pharma (UK) Limited; Biodesix, Inc.; CANbridge Life Sciences, Ltd.; Biogen Idec International GmbH; St. Vincent's Hospital Sydney Limited; and Kyowa Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.